Background: Atherosclerosis is an inflammatory disease. Monocyte chemoattractant protein-1 (MCP-1) is an essential chemokine responsible for the recruitment of monocytes to inflammatory lesions in the vasculature, an initial step of atherosclerosis. Since serum levels of MCP-1 are higher in patients with type 2 diabetes, inhibition of MCP-1 may be a novel therapeutic target for prevention of accelerated atherosclerosis in diabetes. However, little is known about the regulation and determinants of serum MCP-1 levels in patients with diabetes. In this study, we examined the determinants of serum MCP-1 levels in type 2 diabetic patients. Methods: Eighty-six consecutive outpatients with type 2 diabetes (36 male and 50 female; mean age 68.4 ± 9.6) underwent a complete history and physical examination, determination of blood chemistries, MCP-1, turnour necrosis factor-* adiponectin, advanced glycation end products (AGEs), and soluble form of receptor for AGEs (sRAGE). We examined the association between MCP-1 levels and those in anthropometric, metabolic and inflammatory variables in these subjects. Results: Univariate regression analysis showed that serum levels of MCP-1 were positively associated with AGEs (r = 0.386, p < 0.001) and sRAGE (r = 0.315, p < 0.001). After adjusting for age and sex, AGEs (p < 0.001) and sRAGE (p < 0.05) still remained significant. Conclusion: The results demonstrate for the first time that circulating levels of AGEs and sRAGE are independent determinants of serum MCP-1 levels in patients with type 2 diabetes. Our present observations suggest the AGEs-RAGE system may be mainly involved in the elevation of MCP-1 in type 2 diabetic patients.
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism